Capricor Therapeutics (NASDAQ:CAPR) Shares Up 11.6% – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) shares were up 11.6% during mid-day trading on Wednesday. The stock traded as high as $9.25 and last traded at $9.3870. 1,157,035 shares were traded during mid-day trading, a decline of 64% from the average session volume of 3,201,408 shares. The stock had previously closed at $8.41.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Oppenheimer reiterated an “outperform” rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Ladenburg Thalmann & Co. Inc. downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Piper Sandler raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. Finally, Maxim Group downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $30.09.

View Our Latest Stock Analysis on CAPR

Capricor Therapeutics Price Performance

The company has a market capitalization of $530.12 million, a PE ratio of -3.43 and a beta of 0.80. The business has a 50-day moving average of $8.07 and a 200 day moving average of $19.72.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.29). As a group, research analysts anticipate that Capricor Therapeutics, Inc. will post -2.39 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently bought and sold shares of the company. RA Capital Management L.P. boosted its stake in shares of Capricor Therapeutics by 99.9% in the third quarter. RA Capital Management L.P. now owns 3,014,183 shares of the biotechnology company’s stock worth $28,544,000 after buying an additional 1,506,339 shares during the last quarter. Jump Financial LLC raised its position in shares of Capricor Therapeutics by 1,984.9% in the third quarter. Jump Financial LLC now owns 480,286 shares of the biotechnology company’s stock valued at $4,548,000 after buying an additional 457,250 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after purchasing an additional 361,664 shares during the last quarter. Montanova Capital LLC grew its stake in shares of Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after buying an additional 274,184 shares during the period. Finally, Walleye Capital LLC purchased a new position in shares of Capricor Therapeutics during the 1st quarter worth $5,397,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

Featured Stories

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.